A click chemistry route to 2-functionalised PEGylated and cationic beta-cyclodextrins: co-formulation opportunities for siRNA delivery by O'Mahony, Aoife M. et al.
Title A click chemistry route to 2-functionalised PEGylated and cationic beta-
cyclodextrins: co-formulation opportunities for siRNA delivery
Author(s) O'Mahony, Aoife M.; Ogier, Julien R.; Desgranges, Stephane; Cryan,
John F.; Darcy, Raphael; O'Driscoll, Caitríona M.
Publication date 2012-05-21
Original citation O'Mahony, A.M.,Ogier, J.,Desgranges, S.,Cryan, J.F.,Darcy,
R.,O'Driscoll, C.M. (2012) 'A click chemistry route to 2-functionalised
PEGylated and cationic beta-cyclodextrins: co-formulation opportunities
for siRNA delivery'. Organic & Biomolecular Chemistry, 10 :4954-
4960. doi: 10.1039/c2ob25490e
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://dx.doi.org/10.1039/c2ob25490e
Access to the full text of the published version may require a
subscription.
Rights © The Royal Society of Chemistry 2012
Item downloaded
from
http://hdl.handle.net/10468/869
Downloaded on 2017-02-12T08:39:34Z
  
 
1 
 
A click chemistry route to 2-functionalised PEGylated and cationic β-
cyclodextrins: co-formulation opportunities for siRNA delivery 
A.M. O’Mahony 1†,  J.Ogier2†, S. Desgranges2,  J.F. Cryan3,  R. Darcy2 and C.M. O’Driscoll1* 
1
 School of Pharmacy, University College Cork, Cork, Ireland 
2
 Centre for Synthesis and Chemical Biology, School of Chemistry, University College 
Dublin, Dublin 4, Ireland 
3
Dept. of Anatomy and Neuroscience, University College Cork, Cork, Ireland 
*caitriona.odriscoll@ucc.ie 
†
These authors made an equal contribution to this work 
 
Abstract 
A new approach to the synthesis of amphiphilic β-cyclodextrins has used  ‘click’ chemistry to 
selectively modify the secondary 2-hydroxyl group. The resulting extended polar groups can 
be either polycationic or neutral PEGylated groups and these two amphiphile classes are 
compatible in dual cyclodextrin formulations for delivery of siRNA.  When used alone with 
an siRNA, a cationic cyclodextrin was shown to have good transfection properties in cell 
culture. Co-formulation with a PEGylated cyclodextrin altered the physicochemical properties 
of nanoparticles formed with siRNA. Improved particle properties included lower surface 
charges and reduced tendency to aggregate. However, as expected transfection efficiency of 
the cationic vector was lowered by co-formulation with the PEGylated cyclodextrin, requiring 
future surface modification of particles with targeting ligands for effective siRNA delivery. 
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Introduction 
Small interfering RNAs (siRNAs) are capable of specific and efficient gene silencing,
1
 via the 
intracellular RNA interference (RNAi) pathway and are particularly useful for studying gene 
function. They also present a promising therapeutic strategy in a wide variety of diseases. As 
oligonucleotides however, siRNAs show poor cell penetration and limited stability in a 
physiological environment,
2
 therefore considerable research has focused on development of 
vectors for their delivery.  
Cyclodextrins (CDs), cyclomalto-oligosaccharides, are naturally occurring oligosaccharides 
which  are well established pharmaceutical exipients. They offer many advantages as cores 
for the synthesis of non-viral vectors and are by now well established as potential delivery 
agents for therapeutic oligonucleotides.
3-5
  Amphiphilic cationic cyclodextrins have been 
particularly promising.
3, 6-10
 The choice of cationic group and length of amphiphilic chain 
have both been shown to influence binding of pDNA,  properties of the complexes formed 
and transfection efficiency.
4, 8, 11, 12
  
Cationic vectors for siRNA delivery offer several advantages which usually enhance the 
overall results for transfection in cell cultures, namely lowered tendency to aggregate in 
formulations and good (though non-specific) adhesion to cell surfaces. However, there are 
drawbacks associated with such cationic molecules including cellular toxicity and limited 
circulation in vivo.  One approach to overcoming these drawbacks is the modification of 
formulations with poly(ethylene glycol) (PEG), which has been widely reported.
13-15
 The PEG 
provides a surface which is both neutral and non-aggregating, with reduced toxicity. In 
addition, PEG chains are proven as long linkers for exposition of surface ligands which can 
guide delivery to cell receptors.
16
  
Here we have devised a new strategy for synthesis of cationic and neutral PEGylated CDs 
which possess similar amphiphilicity, thus enabling co-assembly and co-formulation to 
provide a PEGylated surface to cationic CD.siRNA nanoparticles. In each series, the polar 
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groups are attached by cuprous-catalysed ‘click’ chemistry. Previously click chemistry has 
been used on the primary side of β-CD gene delivery vectors,17-20 with only limited reports of 
its use on the secondary side.
21
 The extension of any such chemistry to the secondary side 
with its two sets of hydroxyl groups presents a challenge in selectivity, as options are limited 
for introduction of groups at the 2-positions only.
22
  We previously grafted short 
oligo(ethylene oxide) groups at these positions by base-catalysed reaction with ethylene 
carbonate.
3, 23
 However we found this reaction of limited use for chains longer than about two 
to three ethylene oxide units. This may be due to steric hindrance or the formation of ester 
rather than oxo links. Photochemical addition of thiols to 2-alkenylated CDs has lent itself 
well to the introduction of lipid groups at the 2-positions,
6
 but is a less convenient option for 
the attachment of PEG. Here, while thioalkylation is used to provide the hydrophobic groups 
on the primary-OH face as before,
3, 23
 copper (I)-catalysed ‘click’ chemistry is used to attach 
either cationic or PEG groups to form the polar secondary side. This strategy offers many 
possibilities for chemical functionalisation, along with relative ease of synthesis and high 
yield. 
 
In this study we synthesised two CDs, an amphiphilic cationic CD and an amphiphilic 
PEGylated CD and blended these together to yield co-formulations with various degrees of 
PEGylation. Properties of CD.siRNA complexes formed by the cationic amphiphilic 
cyclodextrin alone and by the co-formulated CDs were investigated, including size, charge, 
aggregation, transfection efficiency in Caco2 cells and effects on cell viability.  
 
Results and Discussion 
Compound 3 was synthesised from β-cyclodextrin (Scheme 1) and used as a common 
intermediate for synthesis of the cationic and pegylated cyclodextrins, 5 and 7. Starting 
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from the natural β-cyclodextrin, tert-butyldimethylsilyl chloride selectively introduced 
the TBDMS group at the 6-positions to give 1. Reaction with propargyl bromide yielded 
compound 2, which was reacted with a triphenylphosphine bromine complex to afford the 
bifunctional intermediate 3 with an overall yield of 55%.  
CD 3 posesses two reactive chemical functions: bromo groups for displacement by dodecyl 
thiolate to form the lipidic groups of the final amphiphilic cyclodextrins and azide for “click” 
chemical introduction of the polar groups or PEG groups on the 2-positions. Synthesis of the 
cationic cyclodextrin  5 from 3 started with the  ‘click’ reaction between 3 and tert-butyl 3-
azidopropylcarbamate,  carried out in water with a cuprous catalyst to afford 4. Thioalkylation 
of this with dodecane thiol and deprotection of the Boc-protected amine groups gave 5. The 
PEGylated cyclodextrin 7 was also formed from compound 3, starting with its cuprous-
catalysed reaction with ω-O-methyl-poly(ethylene glycol) azide (Scheme 2). This reactive 
PEG was synthesised in two steps:  monomethyl-PEG 500 was activated using mesyl chloride 
and the mesyl group substituted using sodium azide. The 1,3-dipolar cycloaddition to 3 was 
carried out in water-DMF to yield compound 6, which was again thioalkyated using dodecane 
thiol, to obtain 7.  
The choice of SC12 as the lipid chain at the 6-positions was decided by previous work where 
we observed that self-assembly into bilayers required chains preferably greater than C10, 
whereas above C12 solubility became a problem during the synthesis.
24
 In deciding on the 
extended PEG chain, the potential for immunogenicity of chains longer than PEG 500 was 
kept in mind.
25
  
The use of polyethylene glycol as a surface coating for nanoparticles delivering siRNA is well 
established with small cationic lipid and polymer vectors.
16
 PEG chains have been attached by 
various means, such as chemical reaction with the particle surface
14
 or post-formulation 
insertion  into the outer layers of nanoparticles when the PEG is part of an amphiphile.
26
 
PEGylation of CD-based gene delivery vectors relied upon inclusion of adamantane-PEG into 
the hydrophobic cavities of surface CD groups,
27-29
 rather than directly attaching the PEG to 
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the CD itself. The rationale is that the PEG will provide a charge-neutral and non-aggregating 
surface which will not interact with proteins and which has scope for receptor-ligand 
attachment. Here we have taken another approach, namely the co-formulation of two 
structurally similar vectors, where one, CD 5, is the cationic condensing agent for the siRNA, 
and the other, CD 7, bears the PEG chains. Their structural similarity made it possible to 
apply them as a dual formulation. This strategy enables numerous possibilities for varying the 
formulation by, for example, attaching different length PEG chains to the PEGylated CD, 
attaching cell-specific targeting ligands via the ‘click’ linker or by adjusting the proportions 
of the two CDs incorporated into the CD co-formulation. A similar approach was reported for 
a polyamidoamine-based polymer which was mixed with its PEGylated counterpart, before 
siRNA complexation to yield polyplexes with increasing extent of PEGylation.
30
  
In this paper, firstly the cationic CD 5 was assessed, after complexation with siRNA at 
increasing mass ratios (MR, µg CD 5: µg siRNA). Then CD 5 was co-formulated with CD 7, 
at molar ratio CD 5: CD 7 1:0 to 1:1, yielding a series of CD formulations with varying 
degrees of PEGylation, which were subsequently complexed with siRNA. The properties and 
transfection efficiency of all formulations were assessed. 
The siRNA binding efficiency of the cationic CD 5 was measured using agarose gel 
electrophoresis. Uncomplexed siRNA, used as a control, migrated freely through the gel. At a 
MR of  2, almost no migration was observed and at MR 5 and above there was complete 
binding (results not shown).  Mixing the PEGylated CD 7 with the cationic CD up to 
equimolar ratio, while maintaining the same cationic CD:siRNA mass ratio, did not affect 
complexation. This observation is in contrast to a previous study which showed lack of pDNA 
condensation when a CD-based polymer was PEGylated before complexation 
29  
and another 
whereby a co-formulation consisting of cationic and neutral amphiphilic CDs exhibited poor 
protection of pDNA.
36
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CD:siRNA complex nanoparticles were characterised in terms of size and charge, both of 
which can influence transfection efficiency.
31, 32
 Upon complexation with siRNA at MR 10 
(equivalent to N/P ratio 6.5), the cationic CD 5 (1:0) gave nanoparticles of ~ 240 nm (Fig. 1). 
Smaller particles (< 150nm) were obtained at MR 20 and MR 30 (data not shown).  A 
reduction in particle size was observed upon addition of the PEGylated CD to the 
formulation, in particular at molar ratio 1:1 (Fig. 1). However, the polydispersity index at this 
molar ratio was 0.6, indicating considerable variation in particle size.  
The complexes formed between cationic CD 5 and siRNA had a positive charge (+42 mV) at 
MR 10 (Fig. 1). A positive surface charge contributes to interaction with cellular membrane 
proteoglycans, enabling uptake.
9
 The co-formulations produced by mixing the PEGylated CD 
with the cationic CD had reduced surface charges (+19 mV at molar ratio 1:1), an expected 
shielding effect by the PEG groups at the particle surface. A similar modest effect on charge 
has previously been reported after inclusion of PEG groups into polyethylenimine and 
cyclodextrin-based polymers.
15
 Masking the surface charge of cationic nanoparticles has been 
reported to reduce toxicity 
13, 30
 and minimise non-specific interactions with plasma 
components.
30, 33
 
As well as reducing surface charge of the nanoparticles, incorporation of the PEGylated CD 
had a significant effect on aggregation in OptiMEM transfection medium (Fig. 2). Complexes 
formed with the cationic CD 5 and siRNA (MR10) aggregated in the high salt environment of 
the medium, whereas aggregation was completely prevented in the formulations containing 
the highest proportions of the PEGylated CD 7 (molar ratio 10:1 and 1:1). Therefore stability 
of the formulation was improved by incorporation of the PEGylated CD 7.  
Gene silencing by cationic CD 5 in Caco2 cells was assessed by ability of the CD:siRNA 
complexes to silence an exogenously transfected luciferase reporter plasmid. As shown in 
Fig. 3, the optimal mass ratio for gene silencing was considered to be MR 10, at which a 
significant reduction in luciferase gene expression (76 ± 7 %, *p < 0.05 compared to controls) 
was observed. No further improvement in knockdown was observed at MR 20 (70 ± 8 %). A 
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similar level of knockdown was achieved with the cationic lipid vector Lipofectamine
TM
 
2000.  Neither siRNA alone, nor a non-silencing control siRNA complexed to CD 5 (MR 
10:non-silencing siRNA (MR10/ns)),  mediated gene silencing (Fig. 3). Due to its high 
transfection efficiency, MR 10 was chosen for further experiments using the mixed CD 
formulation.  
On addition of the PEGylated CD, no significant knockdown was observed even with low 
proportions incorporated into the formulation (Fig. 4). This was despite the fact that the 
PEGylated CD 7 had no effect on siRNA binding and did not make  the co-formulated 
complexes totally charge-neutral. It is possible that steric effects of the PEG groups blocked 
charge-interaction with the cell membranes, or that the PEG groups interfered with 
intracellular trafficking. PEGylation of particles formed with DNA  has previously been 
shown to reduce the transfection efficiency of polyethylenimine (PEI) and a linear 
cyclodextrin-containing polymer,
15
 an effect attributed to either reduced cellular uptake or 
impaired intracellular processing. Similarly, a PEGylated lipid vector was unable to deliver 
pDNA or siRNA in vitro as compared to other polymeric or lipid vectors.
34
 However, in 
contrast to these results, another study showed improved gene silencing in vitro with a PEG- 
modified PEI vector,
14
 due to various factors including improved siRNA stability in serum 
and effective endosomal release. When PEG was conjugated to poly-L-lysine by a pH-
sensitive linker, it was  considered to be cleaved in the acidic environment of the endosome so 
that it did not interfere with subsequent siRNA-mediated gene silencing.
13
 Therefore, the 
effects of PEGylation on transfection appear to depend on linker and environment. Also, 
reduction of  transfection in vitro may not be seen in vivo, as was reported by Hatakeyama et 
al. who observed greater activity with a PEGylated lipid vector on systemic administration at 
a tumour site.
35
 
Finally, the cytotoxicity of each of the CD vectors in Caco2 cell cultures was assessed by 
means of an MTT assay. Cells were incubated with increasing concentrations of either 
cationic CD 5 or 7 for four hours. For the cationic CD, at concentrations of up to 30 at 
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least 85% of cells remained viable compared to untreated controls (Fig. 5). The concentration 
of cationic CD used for transfection experiments at CD:siRNA MR10 was approximately 
1.7little or no cytotoxicity was evident at this concentration. The PEGylated CD did not 
affect viability at any of these concentrations, as expected in view of its neutral charge.  
 
Conclusions 
Copper-catalysed ‘click’ chemistry can be used to modify the 2’-hydroxyl position of β-
cyclodextrin in the synthesis of amphiphilic CDs having either cationic primary amine groups 
or lengthy PEG chains on this secondary side.  The two types of amphiphile are compatible 
for co-formulation into nanoparticles with suitable properties for siRNA delivery.  
High levels of gene silencing were achieved in vitro with a cationic CD alone. Nanoparticles 
formed with siRNA using dual formulation of the cationic and a PEGylated  CD displayed 
improved physicochemical properties, namely reduced surface charge and lowered 
aggregation. As expected, the modified particle surface also led to reduced transfection 
efficiency compared with the unPEGylated particles, probably due to steric masking of the 
positive charge by the PEG groups. However, the provision of receptor cell-targeting ligands 
at this surface is expected to restore transfection efficiency, but with the added advantages of 
specificity and lowered toxicity. Meanwhile this approach to  formulating PEGylated vector-
siRNA complexes is a further demonstration of  the advantages of cyclodextrins as core 
molecules for siRNA delivery. 
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Experimental details 
Materials 
Cyclodextrin (Aldrich) was dried for 12 h at 100 ◦C under vacuum. Tert-butyl 3-
azidopropylcarbamate was from LuminoChem, and for safety this low-MW azide was stored 
as a refrigerated solution in dimethylformamide. Monomethoxy PEG500 was from Aldrich. 
Anti-luciferase siRNA (sense strand CUU ACG AGUA CU UCG AdT dT, antisense strand 
UCG AAG UAC UCA GCG UAA GdT dT), and negative siRNA (sense strand UUC UCC 
GAA CGU GUC ACG UdT dt) were from Qiagen. 
Synthesis of modified cyclodextrins 
Heptakis(2-O-propargyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin (2) 
Heptakis(6-O-tert-butyldimethylsilyl)-β-cyclodextrin 1 (1g, 0.52 mmol, 1 eq.) in 100 mL of 
anhydrous DMF was stirred at 0 °C under nitrogen for 30 min. Sodium hydride (125 mg, 5.17 
mmol, 10 eq.) was added slowly, and the solution was stirred at 0°C for 3 h and at r.t. for 12 
h. The solution was then cooled to 0 °C and 550 mg (4.65 mmol, 9 eq.) of propargyl bromide 
(80% in toluene) was added. The resulting solution was stirred for 2 h at 0 °C and 12 h at r.t. 
under N2. The solution was concentrated under reduced pressure, taken into ethyl acetate (50 
mL) and washed with brine (100 mL). The residue after evaporation was purified by column 
chromatography over SiO2 (cyclohexane-ethyl acetate, 3:1) to give 2 as a colourless solid 
(765 mg, 68%). 
1
H NMR (500 MHz, CDCl3) δ 4.94 (d, J = 3.6 Hz, 1H), 4.66 (s, 1H), 4.50 (t, J = 2.4 Hz, 2H), 
3.98 – 3.87 (m, 2H), 3.63 (d, J = 11.2 Hz, 1H), 3.52 (dd, J = 9.0, 4.3 Hz, 3H), 2.42 (t, J = 2.3 
Hz, 1H), 0.84 (s, 9H), 0.00 (d, J = 2.7 Hz, 6H). 
13
C NMR (126 MHz, CDCl3) δ 101.32, 82.13, 
79.69, 79.12, 75.20, 73.62, 71.92, 61.92, 59.56, 27.13, 26.13, 18.49, -4.93. MALDI-MS: 
2224.48 [M+Na]
+
 ; 2240.58 [M+K]
+
. 
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Heptakis(6-bromo-6-deoxy-2-O-propargyl)-β-cyclodextrin (3) 
Triphenylphosphine (1.22 g, 4.0 mmol, 22  eq.) in 50 mL of anhydrous dichloromethane  was 
stirred at 0 °C under nitrogen for 30 min before addition of bromine (180 μL, 3.63 mmol, 20 
eq.) dropwise. The solution was stirred for 30 min at 0 °C and for 2 h at r.t. until a white 
precipitate appeared. The solution was then cooled to 0 °C and 400 mg (0.18 mmol, 1 eq.) of 
heptakis(2-O-propargyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin 2 was added. The 
solution was stirred at r.t. for 12 h, then concentrated under reduced pressure. The residue was 
taken into ethyl acetate (50 mL) and washed with brine (100 mL). The residue after re-
evaporation was purified by column chromatography over SiO2 (cyclohexane-ethyl acetate, 
4:1 to 1:1) to give 3 as a colourless solid (296 mg, 88%). 
1
H NMR (500 MHz, CDCl3) δ 5.07 (d, J = 3.8 Hz, 1H), 4.76 (s, 1H), 4.55 (d, J = 2.3 Hz, 2H), 
3.97 (t, J = 9.2 Hz, 1H), 3.88 – 3.82 (m, 2H), 3.75 – 3.67 (m, 2H), 3.41 (t, J = 9.2 Hz, 1H), 
2.53 (t, J = 2.3 Hz, 1H). 
13
C NMR (126 MHz, CDCl3) δ 101.74, 85.93, 79.21, 78.40, 75.93, 
73.11, 70.84, 59.85, 33.12. MALDI-MS: 1863.63 [M+Na]
+
 ; 1879.84 [M+K]
+
. 
 
Heptakis[6-bromo-2-O-(N-(N-t-butoxycarbonyl-3''-aminopropyl)-1'H-triazole-4'-yl-
methyl)]--cyclodextrin (4) 
Compound 3 (420 mg, 0.23 mmol, 1 eq.) and tert-butyl 3-azidopropylcarbamate (410mg , 
2.05 mmol, 9 eq.) were dissolved in 20mL of DMF and 20mL of water. Copper (II) sulfate 
pentahydrate (45.54mg, 0.18 mmol, 0.8 eq.) was added, then 112 mg (0.57 mmol, 2.5 eq.) of 
sodium ascorbate was added and the solution was stirred at 80 °C for 12 hours. The solution 
was concentrated under reduced pressure and purified by column chromatography over SiO2 
(dichloromethane-methanol 9:1) to give product (715 mg, 96%). 
1
H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 5.34 (s, 1H), 5.04 – 4.81 (m, 3H), 4.43 (t, J = 6.6 
Hz, 2H), 3.87 (t, J = 9.0 Hz, 1H), 3.74 (t, J = 8.6 Hz, 2H), 3.64 – 3.47 (m, 2H), 3.24 (t, J = 8.9 
Hz, 1H), 3.09 (dd, J = 12.0, 5.9 Hz, 2H), 2.12 – 2.00 (m, 2H), 1.37 (s, 9H). 13C NMR (101 
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MHz, CDCl3) δ 156.23, 143.83, 123.91, 101.17, 85.50, 79.27, 79.02, 72.71, 70.63, 65.35, 
47.76, 37.33, 32.92, 30.73, 28.37. 
 
Heptakis[2-O-(N-(N-t-butoxycarbonyl-3''-aminopropyl)-1'H-triazole-4'-yl-methyl)-6-
dodecylthio]--cyclodextrin 
Dodecanethiol (978.7 mg, 4.84 mmol, 22 eq.) and 116.3 mg (4.84 mmol, 22 eq.) of sodium 
hydride were solubilised in 50 mL of anhydrous DMF. The solution was stirred at 80 °C 
under N2 for 2 hours. The solution was then cooled to room temperature and 715.1 mg (0.22 
mmol, 1 eq.) of 4 in 5 mL of anhydrous DMF was added. The solution was stirred overnight 
at 80 °C under N2. The solution was concentrated under reduced pressure and purified by 
column chromatography over SiO2 (dichloromethane-methanol 9:1) to give product (649 mg, 
72%). 
1
H NMR (400 MHz, CDCl3) δ 7.85 (s, 1H), 5.34 (s, 1H), 5.05 (d, J = 12.1 Hz, 1H), 4.90 (d, J 
= 11.8 Hz, 2H), 4.48 (t, J = 6.6 Hz, 2H), 3.89 (t, J = 9.1 Hz, 1H), 3.85 – 3.75 (m, 1H), 3.51 (d, 
J = 8.0 Hz, 1H), 3.43 (t, J = 9.0 Hz, 1H), 3.16 (dd, J = 12.1, 6.0 Hz, 2H), 3.00 – 2.82 (m, 2H), 
2.56 (t, J = 7.4 Hz, 2H), 2.21 – 2.06 (m, 2H), 1.61 – 1.17 (m, 29H), 0.88 (t, J = 6.8 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 156.24, 144.20, 123.77, 101.09, 85.50, 79.28, 73.02, 71.05, 
65.59, 47.86, 37.45, 33.74, 31.96, 30.81, 30.57 – 29.39 (m, 9C), 29.13, 28.45, 22.71, 14.12. 
 
Heptakis[2-O-(N-(3''-aminopropyl)-1'H-triazole-4'-yl-methyl)-6-dodecylthio]--
cyclodextrin trifluoroacetate (5) 
Heptakis[2-O-(N-(N-t-butoxycarbonyl-3''-aminopropyl)-1'H-triazole-4'-yl-methyl)-6-
dodecylthio]--cyclodextrin (649 mg, 0.16 mmol) was dissolved  in 20 mL of DCM and 20 
mL of TFA. The solution was stirred at r.t. under N2 for 6 h. The solution was then 
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concentrated under reduced pressure and dried under high vacuum to give product (628 mg, 
95%).  
1
H NMR (400 MHz, CD3OD / CDCl3) δ 7.98 (s, 1H), 5.05 (s, 1H), 4.92 (dd, J = 54.1, 11.7 
Hz, 2H), 4.56 (t, J = 6.6 Hz, 2H), 3.83 (t, J = 8.8 Hz, 2H), 3.59 – 3.45 (m, 2H), 3.08 – 2.86 
(m, 4H), 2.61 (t, J = 7.0 Hz, 2H), 2.39 – 2.28 (m, 2H), 1.64 – 1.53 (m, 2H), 1.43 – 1.20 (m, 
18H), 0.89 (t, J = 6.7 Hz, 3H). 
13
C NMR (101 MHz, CD3OD/ CDCl3) δ 144.47, 124.85, 
101.13, 85.75, 80.63, 73.25, 71.57, 65.60, 47.62, 37.11, 34.11, 33.90, 32.31, 30.63 – 29.19 
(m, 9C), 28.15, 23.03, 14.33. MALDI-MS: 3394.55 [M+H]
+
 ; 3416.28 [M+Na]
+
. λmax 220 nm. 
FT-IR (cm
-1
): 3414, 2923, 2853, 1133, 1048. 
 
1-O-Mesyl-ω-methoxy-PEG500  
Monomethyl-PEG 500 (1.42 g, 2.57 mmol, 1 eq.) in 80 mL of DCM and 3.2 mL (18.02 
mmol, 7 eq.) of diisopropylethylamine was cooled to 0 °C and 1 mL (12.87 mmol, 5 eq.) of 
mesyl chloride was added. The solution was stirred for 12 h at r.t. under N2. The solution was 
concentrated under reduced pressure and the residue was purified by column chromatography 
over SiO2 (CH2Cl2/methanol, 95:5) to give product  (1.52g, 94%). 
1
H NMR (500 MHz, CDCl3) δ 4.27 – 4.22 (m, 2H), 3.66 – 3.62 (m, 2H), 3.62 – 3.45 (m, 
40H), 3.43 – 3.40 (m, 2H), 3.24 (s, 3H), 2.96 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 71.70, 
70.53 – 69.85 (m), 69.19, 68.77, 58.72, 37.45. MS (ESI-/TOF) m/z: 506.73 (16%) [M-H]- ; 
551.16 (57%) [M-H]
-
 ; 595.28 (73%) [M-H]
-
 ; 639.13 (81%) [M-H]
-
 ; 683.30 (100%) [M-H]
-
 ; 
727.29 (96%) [M-H]
-
 ; 771.21 (65%) [M-H]
-
 ; 859.40 (23%) [M-H]
-
 ; 903.41 (12%) [M-H]
-
. 
 
1-Azido-1-deoxy-ω-methoxy-PEG500  
1-O-Mesyl- ω -methoxy-PEG500 (1.52 g, 2.38 mmol, 1 eq.) was dissolved in 30 mL of DMF. 
620 mg (9.55 mmol, 4 eq.) of sodium azide was added. The solution was heated at 80 °C 
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overnight. The solution was concentrated under reduced pressure and the residue was purified 
by column chromatography over SiO2 (CH2Cl2/methanol, 95:5) to give product (1.21g, 87%). 
1
H NMR (400 MHz, CDCl3) δ 3.70 – 3.50 (m, 48H), 3.50 – 3.44 (m, 2H), 3.34 – 3.28 (m, 
5H). 
13
C NMR (101 MHz, CDCl3) δ 71.85, 70.91 – 70.18 (m), 69.95, 58.93, 50.60. MS 
(ESI
+
/TOF) m/z: 476.15 (15%) [M+Na]
+
 ; 520.14 (51%) [M+Na]
+
 ; 564.14 (100%) [M+Na]
+
 ; 
608.19 (93%) [M+Na]
+
 ; 652.18 (62%) [M+Na]
+
 ; 696.24 (26%) [M+Na]
+
 ; 740.29 (15%) 
[M+Na]
+
. 
 
Heptakis[6-bromo-2-O-(N-(1''-deoxy-ωmethoxy-PEG500- 1''-yl)-1'H-triazole-4'-yl-
methyl)]--cyclodextrin (6) 
Compound 3 (100 mg, 0.054 mmol, 1 eq.) and 1-azido-1-deoxy- ω -methoxy-PEG500  (317 
mg, 0.54 mmol, 10 eq.) were dissolved in 6 mL of DMF and 6 mL of water. 13.5 mg (0.054 
mmol, 1 eq.) of copper (II) sulfate pentahydrate was added. 32 mg (0.16 mmol, 3 eq.) of 
sodium ascorbate was added and the solution was stirred at 80 °C for 12 h. The solution was 
concentrated under reduced pressure and purified by size exclusion column chromatography 
over SEPHADEX LH20 (methanol 100%) to give product (282 mg, 88%). 
1
H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 5.07 – 4.89 (m, 3H), 4.84 (s, 1H), 4.69 – 4.47 (m, 
1H), 4.01 – 3.23 (m, 52H). 13C NMR (101 MHz, CDCl3) δ 143.62, 124.66, 101.35, 85.54, 
78.41, 73.15 – 69.03 (m, 23), 64.90, 58.97, 50.25, 33.01.  
 
Heptakis[2-O-(N-(1''-deoxy-ωmethoxy-PEG500- 1''-yl)-1'H-triazole-4'-yl-methyl)-6-
dodecylthio]--cyclodextrin (7) 
Dodecanethiol (62.24 mg, 0.308 mmol, 15 eq.) and sodium hydride (8 g, 0.35 mmol, 17 eq.) 
were dissolved in 5 mL of anhydrous DMF. The solution was stirred at 80 °C under N2 for 2 
h. The solution was then cooled to room temperature and 114 mg (0.021 mmol, 1 eq.) of 6 in 
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5 mL of anhydrous DMF was added. The solution was stirred overnight at 80 °C under N2. 
The solution was concentrated under reduced pressure and purified by size exclusion column 
chromatography over SEPHADEX LH20 (methanol 100%) to give product (130 mg, quant.). 
1
H NMR (300 MHz, CDCl3) δ 7.81 (s, 1H), 5.07 – 4.83 (m, 2H), 4.78 (s, 1H), 4.63 – 4.44 (m, 
2H), 4.04 – 3.22 (m, 50H), 3.06 – 2.68 (m, 2H), 2.68 – 2.38 (m, 2H), 1.64 – 1.40 (m, 2H), 
1.40 – 1.11 (m, 20H), 0.84 (t, J = 6.5 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 143.95, 124.49, 
101.20, 85.50, 79.05, 74.13–68.27 (m, 24C), 65.04, 58.98, 50.14, 33.64 (2C), 31.90, 30.89–
28.25 (m, 8C), 22.65, 14.07. MALDI –MS: Mavg= 6350 g/mol. λmax 210 nm. FT-IR (cm
-1
): 
3422, 2922, 2855, 1107, 1047. 
 
Preparation and characterisation of CD.siRNA complexes 
Cyclodextrins, dissolved  in chloroform (1mg/ml), were mixed to give required molar ratios. 
The solvent was removed with a gentle stream of nitrogen. Aliquots were stored at -20 ºC 
until required. For preparation of CD:siRNA complexes, CDs were rehydrated with deionised 
water (final concentration 1µg/µl) and sonicated for 1 hour at room temperature (RT), then 
mixed with siRNA in an equal volume of water and used after 20-30 min. For experiments 
involving the cationic and pegylated CD mixes, a fixed cationic CD:siRNA mass ratio of 10 
was chosen. 
Particle size (Z-Ave) and surface charge (ζ-potential) of the CD:siRNA complexes were 
measured by dynamic light scattering, using the Malvern Zetasizer Nano. Samples were 
measured in deionised water and OptiMEM (Invitrogen) (final volume 1ml containing 3µg 
siRNA), in two independent experiments, each with five measurements.  
For measurement of cyclodextrin-siRNA binding by gel electrophoresis, the cyclodextrin and 
siRNA were mixed with loading buffer and deionised water to a final volume of 20µl 
(containing 0.3µg siRNA). Samples were added to wells in a 1% agarose gel containing 
ethidium bromide (0.5µg/ml). Electrophoresis was carried out at 90V for 20 min,with a Tris-
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borate-EDTA buffer. Bands corresponding to the DNA ladder (100 b.p.) and unbound siRNA 
were visualised by UV, using the DNR Bioimaging Systems MiniBis Pro and Gel Capture US 
B2 software. 
 
Cell culture and transfection 
Caco2 (human colon carcinoma) cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% Fetal Bovine Serum (FBS) and L-Glutamine (all from Sigma-
Aldrich), in a 37 ºC, 5% CO2 environment. For transfection, cells were seeded at 1 x 10
5
 
cells/well in 24-well plates, or 3.5 x 10
4
 cells in 96-well plates. Transfection was carried out 
when cultures were ~70% confluent. 
For gene silencing, Caco2 cell cultures were transfected with luciferase reporter plasmid 
pGL3 luciferase (1µg/well) complexed with Lipofectamine
TM
 2000 (Invitrogen) (2.5µl/µg 
pDNA), for 2 hrs. Following this, cultures were washed twice with phosphate-buffered saline 
(PBS, Sigma-Aldrich). siRNA (50nM) alone, or complexed with Lipofectamine
TM
 2000 or 
CD(s), in OptiMEM (Invitrogen) was added to the cultures in serum-containing medium. At 4 
h media were replaced, and a further 20 h later cells were washed with PBS, then lysed with 
400 µl of 1x Reporter Lysis Buffer (Promega Corp.) and frozen at -80 ºC . Lysate was 
collected and centrifuged for 5 min at 13,000 rpm. A sample of the supernatant (20 µl) was 
assayed for expression of luciferase by adding to 100 µl of luciferin (Promega), and 
measuring immediately in a luminometer. Luciferase expression is reported in relative 
luminescence units (RLU) per mg protein, as determined by BCA Protein Assay (Pierce). 
Results are expressed as Mean ± S.E.M. of triplicate values.  
Cell viability in presence of cyclodextrins was determined by the MTT assay, which measures 
the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by 
mitochondrial dehydrogenase in viable cells. Cell cultures were treated with CD 5 or 7 for 4h. 
Media was replaced with 100 µl fresh media and MTT (20µl of a 5mg/ml solution) for four 
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hours, after which the formazon crystals produced were dissolved in 100µl DMSO. 
Absorbance was measured at 590 nm using a UV plate reader. Cell viability was calculated as 
a percentage of untreated control cells. Results are expressed as Mean ± S.D. of triplicate 
values. 
 
Statistics 
GraphPad Prism (San Diego, CA, USA, version 5.0) was used for statistical 
calculations. One-way analysis of variance (ANOVA) was used to compare multiple 
groups followed by Bonferroni’s post hoc test. Statistical significance was set at *p < 
0.05. 
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Scheme 1 Synthesis of the cationic cyclodextrin 5 
(i) TBDMSCl, pyridine, 88% (ii) propargyl bromide, NaH, DMF (iii) PPh3, Br2, CH2Cl2,  (iv) tert-
butyl 3-azidopropylcarbamate, CuSO4.5 H2O, sodium ascorbate, DMF-H2O, 80 °C (v) a) 
dodecanethiol, NaH, 80 °C, b )TFA, CH2Cl2 
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Scheme 2 Synthesis of the pegylated cyclodextrin 7 
(i) 1-Azido-1-deoxy-ω-methoxy-PEG500 , CuSO4, 5 H2O, sodium ascorbate, DMF-H2O, 80 °C (ii) 
dodecanethiol, NaH, 80 °C. 
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Fig. 1 Effects of molar ratio of cationic CD 5 to pegylated CD 7 on the size (Z-Ave) and charge (zeta 
potential) of  CD:siRNA complexes (mass ratio cationic CD 5:siRNA=10) in water.  Results are 
expressed as Mean ± S.D. (n=5). 
 
 
 
 
Fig. 2 Effect of molar ratio of cationic CD 5 to pegylated CD 7 on size (Z-Ave) of CD:siRNA 
complexes in deionised water and OptiMEM (mass ratio cationic CD 5:siRNA=10). Results are 
expressed as Mean ± S.D. (n=5). 
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Fig. 3 Silencing of luciferase reporter gene expression in Caco2 cells with cationic CD 5 at increasing 
mass ratios (MR, cationic CD 5:siRNA). Lipofectamine 2000 (Lf 2000) was included as a positive 
control. Results are expressed as Mean ± S.E.M. (n=3). * p < 0.05 relative to untreated cells   
 
 
 
 
 
Fig. 4 Effects of molar ratio of cationic CD 5 to pegylated CD 7 on silencing of luciferase reporter 
gene expression in Caco2 cells at mass ratio cationic CD 5:siRNA=10.  Results are expressed as Mean 
± S.E.M. (n=3). * p < 0.05 relative to untreated cells. 
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Fig. 5 Effect of cationic CD 5 (solid line) and pegylated CD 7 (dotted line) on viability of Caco2 cells 
over concentration range 0 to 60 µM. Cells were treated for 4 hours and cell viability was assessed by 
an MTT assay. Results are expressed as Mean ± S.D. (n=3). 
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